Literature DB >> 20564111

Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11).

Jaffer A Ajani1, Kathryn A Winter, Leonard L Gunderson, John Pedersen, Al B Benson, Charles R Thomas, Robert J Mayer, Michael G Haddock, Tyvin A Rich, Christopher G Willett.   

Abstract

BACKGROUND: Only 4 prospective randomized phase 3 trials have been reported for anal cancer. A prognostic factor analysis for anal cancer from a prospective database has been published from only 1 study (N = 110). To confirm and uncover new prognostic factors, we analyzed the prospective database of intergroup RTOG 98-11.
METHODS: Univariate and multivariate analyses of the baseline characteristics for 5-year overall survival (OS) and disease-free survival (DFS) were carried out. Various combinations of tumor diameter and clinically positive nodes (N(+)) were analyzed to identify subgroups.
RESULTS: A total of 644 were assessable and analyzed. Tumor diameter >5 cm was associated with poorer 5-year DFS (P = .0003) and poorer 5-year OS (P = .0031), and N(+) was associated with poorer 5-year DFS (P </= .0001) and poorer 5-year OS (P = </= .0001) in the multivariate analysis. In stratified analyses, N(+) had more adverse influence on DFS and OS than did tumor diameter. Patients with >5-cm tumor and N(+) had the worst DFS (only 30% at 3 years compared with 74% for the best group; <5 cm primary and N0) and OS (only 48% at 4 years compared with 81% for the best group; <5 cm primary and N0). Men had worse DFS (P = .02) and OS (P = .016). These factors maintained their influence in each treatment arm.
CONCLUSIONS: This prospective prognostic factor analysis establishes tumor diameter as an independent prognosticator of poorer 5-year DFS and OS and confirms N(+) and male sex as poor prognostic factors. This analysis also uncovers novel subgroups (derived from combining prognostic factors) with incremental worsening of DFS and OS. Cancer 2010. (c) 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20564111      PMCID: PMC3831519          DOI: 10.1002/cncr.25188

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.

Authors: 
Journal:  Lancet       Date:  1996-10-19       Impact factor: 79.321

2.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

3.  Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications.

Authors:  D Peiffert; P Bey; M Pernot; F Guillemin; E Luporsi; S Hoffstetter; P Aletti; P Boissel; M A Bigard; D Dartois; F Baylac
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-15       Impact factor: 7.038

4.  Carcinoma of the anal canal. A clinical and pathologic study of 188 cases.

Authors:  B M Boman; C G Moertel; M J O'Connell; M Scott; L H Weiland; R W Beart; L L Gunderson; R J Spencer
Journal:  Cancer       Date:  1984-07-01       Impact factor: 6.860

5.  Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.

Authors:  M Flam; M John; T F Pajak; N Petrelli; R Myerson; S Doggett; J Quivey; M Rotman; H Kerman; L Coia; K Murray
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

6.  Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314.

Authors:  B Sischy; R L Doggett; J M Krall; D G Taylor; W T Sause; J A Lipsett; H G Seydel
Journal:  J Natl Cancer Inst       Date:  1989-06-07       Impact factor: 13.506

7.  Radiation treatment of epidermoid cancer of the anus.

Authors:  C Svensson; S Goldman; B Friberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-09-01       Impact factor: 7.038

8.  Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy.

Authors:  W E Longo; A M Vernava; T P Wade; M A Coplin; K S Virgo; F E Johnson
Journal:  Ann Surg       Date:  1994-07       Impact factor: 12.969

9.  US intergroup anal carcinoma trial: tumor diameter predicts for colostomy.

Authors:  Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

10.  Treatment of epidermoid carcinoma of the anal canal.

Authors:  M J Greenall; S H Quan; C Urmacher; J J DeCosse
Journal:  Surg Gynecol Obstet       Date:  1985-12
View more
  32 in total

1.  The effect of dose escalation for large squamous cell carcinomas of the anal canal.

Authors:  R N Prasad; J Elson; J Kharofa
Journal:  Clin Transl Oncol       Date:  2018-04-05       Impact factor: 3.405

2.  ACR Appropriateness Criteria®-Anal Cancer.

Authors:  Theodore S Hong; Jennifer L Pretz; Joseph M Herman; May Abdel-Wahab; Nilofer Azad; A William Blackstock; Prajnan Das; Karyn A Goodman; Salma K Jabbour; William E Jones; Andre A Konski; Albert C Koong; Miguel Rodriguez-Bigas; William Small; Charles R Thomas; Jennifer Zook; W Warren Suh
Journal:  Gastrointest Cancer Res       Date:  2014-01

3.  Radiotherapy with or without chemotherapy in the treatment of anal cancer: 20-year experience from a single institute.

Authors:  K Fakhrian; T Sauer; S Klemm; C Bayer; B Haller; M Molls; H Geinitz
Journal:  Strahlenther Onkol       Date:  2012-11-15       Impact factor: 3.621

4.  Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival.

Authors:  Letizia Deantonio; Maria Elisa Milia; Tiziana Cena; Gianmauro Sacchetti; Carola Perotti; Marco Brambilla; Lucia Turri; Marco Krengli
Journal:  Radiol Med       Date:  2015-07-01       Impact factor: 3.469

5.  A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer.

Authors:  Renata D'Alpino Peixoto; Dante D Wan; Devin Schellenberg; Howard J Lim
Journal:  J Gastrointest Oncol       Date:  2016-08

6.  Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Authors:  Leonard L Gunderson; Kathryn A Winter; Jaffer A Ajani; John E Pedersen; Jennifer Moughan; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544

Review 7.  Anal cancer: are we making progress?

Authors:  Ajay Aggarwal; Simon Duke; Rob Glynne-Jones
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

8.  Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer.

Authors:  Mathieu Gauthé; Marion Richard-Molard; Juliette Fayard; Jean-Louis Alberini; Wulfran Cacheux; Astrid Lièvre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-09       Impact factor: 9.236

9.  Comparison of elective inguinal node irradiation techniques in anal cancer.

Authors:  Jihye Cha; Jinsil Seong; Ki Chang Keum; Chang Geol Lee; Woong Sub Koom
Journal:  Radiat Oncol J       Date:  2011-12-28

10.  Reasons for delays in diagnosis of anal cancer and the effect on patient satisfaction.

Authors:  Sharon Chiu; Kurian Joseph; Sunita Ghosh; Rose-Marie Cornand; Dan Schiller
Journal:  Can Fam Physician       Date:  2015-11       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.